The global nanobiotechnology market is projected to grow from USD 172.81 billion in 2024 to USD 420.2 billion by 2034, driven by healthcare demand, R&D funding, and technological innovations in drug delivery and medical applications.

Nanobiotix, a late-stage clinical biotechnology company, has been admitted to the CAC Mid 60 and SBF 120 indices on Euronext Paris, effective December 19, 2025, which is expected to increase investor visibility and market presence.

French biotechnology company Nanobiotix has been admitted to the CAC Mid 60 and SBF 120 indices, effective December 19, 2025, which is expected to increase investor visibility and market presence.

French biotechnology company Nanobiotix has experienced a 660% stock surge in 2025, driven by promising cancer-fighting drug development and strategic partnerships with Johnson & Johnson and Healthcare Royalty Partners.

NANOBIOTIX reported promising Phase 1 clinical trial results for JNJ-1900 (NBTXR3), a nanoparticle-based cancer treatment, showing favorable safety profile and potential efficacy in treating recurrent/metastatic head and neck squamous cell carcinoma patients, both naive and resistant to anti-PD-1 treatments.

A Phase 1 study evaluated JNJ-1900 (NBTXR3), a nanoparticle treatment activated by radiation therapy, in combination with anti-PD-1 immunotherapy for recurrent/metastatic head and neck squamous cell carcinoma. Results showed promising disease control rates and potential for overcoming anti-PD-1 resistance.

Nanobiotix announced the presentation of full results from a Phase 1 study evaluating JNJ-1900 (NBTXR3) in patients with locally advanced or borderline resectable pancreatic cancer. The study will be presented at the ESTRO 2025 conference, and Nanobiotix will host a conference call to discuss the data.

Nanobiotix announced the presentation of full results from a Phase 1 study evaluating JNJ-1900 (NBTXR3) in locally advanced or borderline resectable pancreatic cancer. The company will host a conference call to discuss the results.

The global nano-biotechnology market is poised for significant growth, driven by advancements in drug delivery, diagnostics, and gene therapy. Key segments include nanomaterials, devices, and reagents, with applications in drug delivery, diagnostics, imaging, gene delivery, and tissue engineering.

Nanobiotix provided an update on its operational progress and financial results for Q3 2024, including the transfer of sponsorship for the NANORAY-312 head and neck cancer study to Janssen, the expansion of its Supervisory Board, and upcoming milestones for its NBTXR3 and Curadigm programs.

The squamous cell carcinoma (SCC) market is experiencing robust growth due to the increasing incidence of the disease and advancements in treatment options. Over 75 companies are working on 80+ pipeline therapies to improve the SCC treatment landscape.

U.S. stock futures were lower this morning, with the Dow futures falling over 150 points on Thursday. Shares of CarMax, Inc. (NYSE: KMX) fell sharply in today’s pre-market trading after the company reported lower-than-expected fourth-quarter earnings. CarMax posted quarterly earnings of 32 cents per share, missing market estimates of 49 cents per share. The company’s quarterly sales came in at $5.63 billion versus expectations of $5.79 billion, according to data from Benzinga Pro. CarMax shares dipped 9.1% to $72.06 in pre-market trading. Here are some big stocks recording losses in today’s pre-market ...